title: Clinical value of antiplatelet therapy in patients with acute coronary syndromes and in percutaneous coronary intervention.
abstract: Dual antiplatelet therapy with aspirin and clopidogrel is recommended in all patients who have had an acute coronary syndrome or who undergo percutaneous coronary intervention to prevent further ischemic events. Resistance or reduced responsiveness to aspirin and/or clopidogrel has been associated with adverse cardiovascular outcomes, including stent thrombosis. There have been significant advances in this field, which aim to overcome antiplatelet resistance, including the development of new antiplatelet agents. The rationale for dual antiplatelet therapy, the impact of suboptimal efficacy and the potential ways of overcoming resistance or variability in response to antiplatelet agents will be reviewed in this article.
authors.affiliation: West of Scotland Regional Heart & Lung Centre, Golden Jubilee National Hospital, Glasgow, UK.
authors.forename: Fiona
authors.initials: F
authors.lastname: Foo
authors.forename: Keith G
authors.initials: KG
authors.lastname: Oldroyd
mesh_terms: D054058:Acute Coronary Syndrome / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology; D001792:Blood Platelets / Q000187:drug effects / Q000502:physiology; D003331:Coronary Vessels / Q000187:drug effects* / Q000503:physiopathology; D006801:Humans; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D015607:Stents / Q000009:adverse effects; D013927:Thrombosis / Q000209:etiology
chemical_list: D010975:Platelet Aggregation Inhibitors